Retinal Photocoagulation Does Not Influence Intraocular Levels of IGF-I, IGF-II and IGF-BP3 in Proliferative Diabetic Retinopathy - Evidence for Combined Treatment of PDR with Somatostatin Analogues and Retinal Photocoagulation?

 

 Buy Article Permissions and Reprints

Retinal photocoagulation reduces the incidence of severe visual loss in proliferative diabetic retinopathy (PDR). Reduced levels of VEGF/VPF might result in an improved function of the blood-retina barrier and cause a decrease of blood derived intraocular growth factors such as IGF-I. This study investigates whether retinal photocoagulation is able to normalize the concentrations of IGF-I, IGF-II and IGF-BP3 in the vitreous humor of patients undergoing vitrectomy. Levels of IGFs and the permeability marker, albumin, were measured in serum and vitreous of 52 patients. Three groups were compared: controls without proliferating eye disease (n = 19) and patients with PDR with (PDR+; n = 25) and without (PDR-; n = 8) previous retinal photocoagulation. IGF-I, IGF-II, IGF-BP3 and albumin were determined by immunological methods and were confirmed to be increased in patients with PDR compared to controls. Retinal photocoagulation influenced neither the intraocular concentration of the permeability marker albumin (PDR+: 253.2 ± 46 mg/dl; PDR-: 256.4 ± 66.5 mg/dl) nor the levels of IGFs (PDR+: IGF-I: 1.2 ± 0.1ng/ml; p = 0.38; IGF-II: 34.8 ± 2.2 ng/ml; p = 0.1; IGF-BP3: 75.7 ± 9.7 ng/ml; p = 0.27; PDR-: IGF-I: 1.1 ± 0.2 ng/ml; IGF-II: 29.3 ± 5.2 ng/ml; IGF-BP3: 61.5 ± 18.3 ng/ml). Systemic levels of albumin and IGFs were not changed significantly by retinal photocoagulation. These results demonstrate that previous retinal photocoagulation in patients undergoing vitrectomy does not functionally reestablish the blood-retina barrier despite decreases in VEGF/VPF. The lack of influence on intraocular concentrations of the serum-derived growth factors, IGF-I, IGF-II and IGF-BP3, might in part explain the failure of previous photocoagulation in the investigated patients. These results suggest that a combined treatment with retinal photocoagulation and growth hormone-lowering drugs, such as somatostatin analogues, could be a useful treatment, which may prevent further loss of visual acuity in patients with PDR.

References

• 1 Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.  N Engl J Med. 1988;  318 1315-1321
  CrossrefPubMedGoogle Scholar
• 2 Hunt J V, Smith C C, Wolff S P. Autooxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose.  Diabetes. 1990;  39 1420-1424
  CrossrefPubMedGoogle Scholar
• 3 Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer A FH. Regulation of protein kinase C by short term hyperglycemia in human platelets in vivo and in vitro. .  Diabetologia. 2001;  44 (2) 188-195
  CrossrefPubMedGoogle Scholar
• 4 DeRubertis F R, Craven P A. Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy.  Diabetes. 1994;  43 (1) 1-8
  PubMedGoogle Scholar
• 5 Aiello L P, Avery R L, Arigg P G, Keyt B A, Jampel H D, Shah S T, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.  N Engl J Med. 1994;  331 1480-1487
  CrossrefPubMedGoogle Scholar
• 6 Aiello L P, Bursell S E, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.  Diabetes. 1997;  46 1473-1480
  PubMedGoogle Scholar
• 7 Spranger J, Meyer-Schwickerath R, Klein M, Schatz H, Pfeiffer A. Deficient activation and different expression of transforming growth factor-beta isoforms in active proliferative diabetic retinopathy and neovascular eye disease.  Exp Clin Endocrinol Diabetes. 1999;  107 (1) 21-28
  PubMedGoogle Scholar
• 8 Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown.  Diabetes. 1997;  46 (Suppl 2) S26-30
  PubMedGoogle Scholar
• 9 Patz A. Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture.  Am J Ophthalmol. 1982;  94 (6) 715-743
  PubMedGoogle Scholar
• 10 . Early Treatment Diabetic Retinopathy Study Research Group . Early Photocoagulation for Diabetic Retinopathy: ETDRS Report Number 9.  Ophthalmology. 1991;  98 Supplement 766-785
  CrossrefPubMedGoogle Scholar
• 11 Spranger J, Hammes H -P, Preissner K T, Schatz H, Pfeiffer A FH. Release of the angiogenesis inhibitor angiostatin in patients with proliferative diabetic retinopathy: Association with retinal photocoagulation.  Diabetologia. 2000;  43 1404-1407
  CrossrefPubMedGoogle Scholar
• 12 Spranger J, Buhnen J, Jansen V, Krieg M, Meyer-Schwickerath R, Blum W F, et al. Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 in proliferative diabetic retinopathy.  Horm Metab Res. 2000;  32 (5) 196-200
  PubMedGoogle Scholar
• 13 Chantelau E. Evidence that upregulation of serum IGF-I concentration can trigger acceleration of diabetic retinopathy.  Br J Ophthalmol. 1998;  82 (7) 725-730
  PubMedGoogle Scholar
• 14 Meyer-Schwickerath R, Pfeiffer A, Blum W F, Freyberger H, Klein M, Losche C, et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.  J Clin Invest. 1993;  92 (6) 2620-2625
  CrossrefPubMedGoogle Scholar
• 15 Kirkegaard C, Norgaard K, Snorgaard O, Bek T, Larsen M, Lund Andersen H. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin dependent) diabetes mellitus.  Acta Endocrinologica. 1990;  122 766-772
  PubMedGoogle Scholar
• 16 Smith L EH, Kopchick J J, Chen W, Knapp J, Kinose F, Daley D, et al. Essential role of growth hormone in ischemia-induced retinal neovascularization.  Science. 1997;  276 1706-1709
  CrossrefPubMedGoogle Scholar
• 17 Stone J, Itin A, Alon T, Pe’er J, Gnessin H, Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia.  J Neurosci. 1995;  15 (7 Pt 1) 4738-4747
  PubMedGoogle Scholar
• 18 Pierce E A, Avery R L, Foley E D, Aiello L P, Smith L E. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization.  Proc Natl Acad Sci USA. 1995;  92 (3) 905- 909
  CrossrefPubMedGoogle Scholar
• 19 Robinson G S, Pierce E A, Rook S L, Foley E, Webb R, Smith L E. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.  Proc Natl Acad Sci USA. 1996;  93 (10) 4851-4856
  CrossrefPubMedGoogle Scholar
• 20 Aiello L P, Bursell S E, Clermont A, Duh E, Ishii H, Takagi C, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor.  Diabetes. 1997;  46 (9) 1473-1480
  PubMedGoogle Scholar
• 21 Sharp P S, Fallon T J, Brazier J, Sandler L M, Joplin G F, Kohner E M. Long term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy.  Diabetologia. 1987;  30 199-207
  CrossrefPubMedGoogle Scholar
• 22 Smith L E, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor.  Nat Med. 1999;  5 (12) 1390-1395
  Google Scholar

A. F. H. Pfeiffer

German Institute of Human Nutrition, Potsdam
Department of Clinical Nutrition

Arthur-Scheunert-Allee 114 - 116
14558 Bergholz-Rehbrücke
Germany


Phone: Phone:+ 49 (33200) 88505

Fax: Fax:+ 49 (33200) 88555

Email: E-mail:AFHP@www.dife.de